AU2009213748B9 - Method of treating prostate cancer with the GnRH antagonist degarelix - Google Patents

Method of treating prostate cancer with the GnRH antagonist degarelix Download PDF

Info

Publication number
AU2009213748B9
AU2009213748B9 AU2009213748A AU2009213748A AU2009213748B9 AU 2009213748 B9 AU2009213748 B9 AU 2009213748B9 AU 2009213748 A AU2009213748 A AU 2009213748A AU 2009213748 A AU2009213748 A AU 2009213748A AU 2009213748 B9 AU2009213748 B9 AU 2009213748B9
Authority
AU
Australia
Prior art keywords
degarelix
treatment
subject
patients
prostate cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2009213748A
Other languages
English (en)
Other versions
AU2009213748B2 (en
AU2009213748A1 (en
Inventor
Per Cantor
Jens-Kristian Slott Jensen
Tine Kold Olesen
Bo-Eric Persson
Egbert A. Van Der Meulen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ferring International Center SA
Original Assignee
Ferring International Center SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39718285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2009213748(B9) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring International Center SA filed Critical Ferring International Center SA
Publication of AU2009213748A1 publication Critical patent/AU2009213748A1/en
Application granted granted Critical
Publication of AU2009213748B2 publication Critical patent/AU2009213748B2/en
Publication of AU2009213748B9 publication Critical patent/AU2009213748B9/en
Priority to AU2014203174A priority Critical patent/AU2014203174B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2009213748A 2008-02-11 2009-02-10 Method of treating prostate cancer with the GnRH antagonist degarelix Active AU2009213748B9 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014203174A AU2014203174B2 (en) 2008-02-11 2014-06-12 Method of treating prostate cancer with the gnrh antagonist degarelix

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2774108P 2008-02-11 2008-02-11
US61/027,741 2008-02-11
EP08250703 2008-02-29
EP08250703.9 2008-02-29
PCT/IB2009/000350 WO2009101530A1 (en) 2008-02-11 2009-02-10 Method of treating prostate cancer with the gnrh antagonist degarelix

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014203174A Division AU2014203174B2 (en) 2008-02-11 2014-06-12 Method of treating prostate cancer with the gnrh antagonist degarelix

Publications (3)

Publication Number Publication Date
AU2009213748A1 AU2009213748A1 (en) 2009-08-20
AU2009213748B2 AU2009213748B2 (en) 2014-03-13
AU2009213748B9 true AU2009213748B9 (en) 2014-05-22

Family

ID=39718285

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2009213748A Active AU2009213748B9 (en) 2008-02-11 2009-02-10 Method of treating prostate cancer with the GnRH antagonist degarelix
AU2009213751A Active AU2009213751B2 (en) 2008-02-11 2009-02-10 Treatment of metastatic stage prostate cancer with degarelix

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2009213751A Active AU2009213751B2 (en) 2008-02-11 2009-02-10 Treatment of metastatic stage prostate cancer with degarelix

Country Status (25)

Country Link
US (16) US20090203623A1 (enExample)
EP (7) EP2249859B1 (enExample)
JP (11) JP5876652B2 (enExample)
KR (8) KR20220009504A (enExample)
CN (4) CN101998861A (enExample)
AU (2) AU2009213748B9 (enExample)
BR (2) BRPI0908127A2 (enExample)
CA (3) CA2714444A1 (enExample)
CY (3) CY1115561T1 (enExample)
DK (3) DK2650012T3 (enExample)
EA (4) EA020543B1 (enExample)
ES (3) ES2479441T3 (enExample)
HK (1) HK1198243A1 (enExample)
HR (3) HRP20140665T1 (enExample)
IL (3) IL207295A (enExample)
JO (1) JOP20090061B1 (enExample)
MX (2) MX2010008817A (enExample)
NZ (4) NZ603958A (enExample)
PL (3) PL2650012T3 (enExample)
PT (3) PT2249859E (enExample)
RU (2) RU2504394C2 (enExample)
SI (3) SI2505204T1 (enExample)
TW (2) TWI539959B (enExample)
WO (2) WO2009101533A1 (enExample)
ZA (1) ZA201005697B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
JO3525B1 (ar) * 2008-02-11 2020-07-05 Ferring Int Center Sa علاج سرطان البروستاتا في المرحلة النقيلية بدواء ديجاريليكس
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
EP2424503B1 (en) * 2009-05-01 2017-07-05 Ferring BV Composition for the treatment of prostate cancer
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) * 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
FR2964323B1 (fr) * 2010-09-08 2012-11-09 Jean Pierre Raynaud Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate
EP2447276A1 (en) 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
DK2632934T3 (en) 2010-10-27 2017-01-23 Ferring Bv Process for the preparation of Degarelix and its intermediates
JO3755B1 (ar) 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
BR112013023050A8 (pt) * 2011-03-09 2018-09-25 G Pestell Richard antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um composto candidato, para produzir in vitro células epiteliais primárias, para diagnosticar câncer de próstata, para selecionar um tratamento para um indivíduo tendo um câncer/tumor de próstata, linhagem de célula, e, modelo animal
CN102204889B (zh) * 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
WO2013104745A1 (en) * 2012-01-13 2013-07-18 Ferring Bv Pharmaceutical composition
AU2013262977A1 (en) 2012-05-14 2015-01-22 Prostagene, Llc Using modulators of CCR5 for treating cancer
PL4512389T1 (pl) 2012-06-01 2025-09-01 Ferring B.V. Produkt leczniczy degareliksu
LT3305285T (lt) 2012-09-26 2020-12-10 Aragon Pharmaceuticals, Inc. Anti-androgenai, skirti gydyti nametastazavusį kastracijai atsparų prostatos vėžį
US9758528B2 (en) 2012-09-28 2017-09-12 Takeda Pharmaceutical Company Limited Production method of thienopyrimidine derivative
WO2014143669A1 (en) 2013-03-15 2014-09-18 AbbVie Inc . Compositions for use in treating heavy menstrual bleeding and uterine fibroids
US20140358576A1 (en) * 2013-05-15 2014-12-04 Adverse Events, Inc. System and method for surveillance and evaluation of safety risks associated with medical interventions
EP3185881B1 (en) 2014-08-26 2022-03-09 Betanien Hospital Methods, agents and compositions for treatment of inflammatory conditions
EP3294301A4 (en) * 2015-05-12 2019-01-09 Drexel University COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF CANCER METASTAS AND METHODS THEREWITH
PT3518932T (pt) 2016-09-30 2025-01-16 Takeda Pharmaceuticals Co Tratamento do cancro da próstata
KR20190112029A (ko) * 2017-01-30 2019-10-02 안테브 리미티드 적어도 하나의 gnrh 길항제를 포함하는 조성물
CA3079135A1 (en) 2017-10-16 2019-04-25 Arturo Molina Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
EP3781167A4 (en) 2018-04-19 2022-02-23 Abbvie Inc. METHODS OF TREATMENT OF HEAVY PERIODS
CA3107597A1 (en) * 2018-08-01 2020-02-06 Abbvie Inc. Dosing regimens for elagolix
RU2731002C1 (ru) * 2019-10-22 2020-08-26 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский клинический институт им. М.Ф. Владимирского" (ГБУЗ МО МОНИКИ им. М.Ф. Владимирского) Способ лечения рака предстательной железы
CN116407494B (zh) * 2023-03-02 2024-07-09 山东大学齐鲁医院 一种醋酸地加瑞克注射液及其制备方法、用途

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
ZA735680B (en) * 1972-09-21 1974-07-31 Hoffmann La Roche Polypeptides
US4072668A (en) 1973-11-06 1978-02-07 The Salk Institute For Biological Studies LH-RH Analogs
EP0002749B2 (en) 1977-12-26 1987-08-12 IHARA CHEMICAL INDUSTRY Co., Ltd. Process for producing aromatic monocarboxylic acid
US5296468A (en) 1989-10-30 1994-03-22 The Salk Institute For Biological Studies GnRH analogs
DE593491T1 (de) 1991-04-25 1994-11-17 Romano S.-Cergue Deghenghi LHRH-Antagonisten.
ES2159516T5 (es) 1992-02-12 2005-05-01 Daikyo Gomu Seiko Ltd. Un instrumento medico.
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
DE4305225A1 (de) * 1993-02-19 1994-08-25 Asta Medica Ag Neues Herstellverfahren für Cetrorelix Lyophilisat
US5506207A (en) 1994-03-18 1996-04-09 The Salk Institute For Biological Studies GNRH antagonists XIII
US5595760A (en) * 1994-09-02 1997-01-21 Delab Sustained release of peptides from pharmaceutical compositions
JP3688381B2 (ja) 1995-03-10 2005-08-24 株式会社東芝 光ディスク原盤露光装置
US6379669B1 (en) 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
US5710246A (en) 1996-03-19 1998-01-20 Abbott Laboratories Process for intermediates for the synthesis of LHRH antagonists
US5860957A (en) * 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
US5925730A (en) 1997-04-11 1999-07-20 Ferring Bv GnRH antagonists
US5821230A (en) * 1997-04-11 1998-10-13 Ferring Bv GnRH antagonist decapeptides
AU1590699A (en) 1997-11-20 1999-06-15 Ortho-Mcneil Pharmaceutical, Inc. Liquid phase process for the preparation of gnrh peptides
FR2776520B1 (fr) 1998-03-25 2000-05-05 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques destinees a la liberation prolongee de peptides et leur procede de preparation
MXPA01000674A (es) 1998-07-20 2002-04-08 Peptech Ltd Formulacion de bioimplante.
AU6011001A (en) * 2000-03-14 2001-09-24 Zentaris Ag Novel lhrh-antagonists, production and use thereof as medicament
US20040198706A1 (en) 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US20020103131A1 (en) 2001-01-26 2002-08-01 Jacobson Jill D. Prevention of diabetes by administration of GnRH antagonists
WO2002098897A2 (en) * 2001-06-01 2002-12-12 Cornell Research Foundation, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
GB0117057D0 (en) * 2001-07-12 2001-09-05 Ferring Bv Pharmaceutical composition
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US20070015713A1 (en) 2005-07-14 2007-01-18 Voyager Pharmaceutical Corporation Methods for treating prostate cancer
US20060234918A1 (en) * 2001-12-19 2006-10-19 Voyager Pharmaceutical Corporation Methods for treating and preventing cancers that express the hypothalamic-pituitary-gonadal axis of hormones and receptors
SE0104463D0 (sv) 2001-12-29 2001-12-29 Carlbiotech Ltd As Mellanprodukter för syntes af LHRH-antagonister, sätt att framställa dem och sätt för framställning av LHRH-antagonister
CN1411803A (zh) 2002-08-29 2003-04-23 四川大学 制备前体脂质体的方法及其装置
KR100633280B1 (ko) 2002-09-27 2006-10-16 젠타리스 게엠베하 약제학적 활성 펩티드의 서방형 투여 형태 및 이의 제조 방법
GB0223367D0 (en) * 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
AR042815A1 (es) * 2002-12-26 2005-07-06 Alza Corp Dispositivo de suministro de agente activo que tiene miembros compuestos
EP1674082A1 (de) * 2004-12-22 2006-06-28 Zentaris GmbH Verfahren zur Herstellung von sterilen Suspensionen oder Lyophilisaten schwerlöslicher basischer Peptidkomplexe, diese enthaltende pharmazeutische Formulierungen sowie ihre Verwendung als Arzneimittel
WO2006069779A1 (en) 2004-12-30 2006-07-06 F. Hoffmann-La Roche Ag Preparing of peptides with excellent solubility
US8158152B2 (en) 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007130809A2 (en) 2006-05-06 2007-11-15 Volodymyr Brodskyy An automatic injectable drug mixing device
EP1891964A1 (en) 2006-08-08 2008-02-27 AEterna Zentaris GmbH Application of initial doses of LHRH analogues and maintenance doses of LHRH antagonists for the treatment of hormone-dependent cancers and corresponding pharmaceutical kits
EP1967202A1 (en) 2007-03-05 2008-09-10 AEterna Zentaris GmbH Use of LHRH Antagonists for the Treatment of Lower Urinary Tract Symptoms, in particular Overactive Bladder and/or Detrusor Overactivity
IL182922A0 (en) 2007-05-02 2007-09-20 Medimop Medical Projects Ltd Automatic liquid drug reconstitution apparatus
US8283331B2 (en) 2007-10-09 2012-10-09 Children's Medical Center Corporation Methods to regulate miRNA processing by targeting Lin-28
NZ601913A (en) 2008-01-15 2014-02-28 Abbott Gmbh & Co Kg Powdered protein compositions and methods of making same
WO2009102720A1 (en) * 2008-02-11 2009-08-20 Safety Syringes, Inc. Reconstitution means for safety device
JOP20090061B1 (ar) 2008-02-11 2021-08-17 Ferring Int Center Sa طريقة معالجة سرطان البروستاتا بمضادات الهرمونات التناسلية GnRH
KR101621725B1 (ko) 2009-04-24 2016-05-17 폴리펩타이드 라보라토리즈 에이/에스 데가렐릭스의 제조 방법
EP2424503B1 (en) * 2009-05-01 2017-07-05 Ferring BV Composition for the treatment of prostate cancer
TW201043221A (en) * 2009-05-06 2010-12-16 Ferring Int Ct Sa Kit and method for preparation of a Degarelix solution
US20110039787A1 (en) 2009-07-06 2011-02-17 Ferring International Center S.A. Compositions, kits and methods for treating benign prostate hyperplasia
WO2011066386A1 (en) 2009-11-25 2011-06-03 Novetide, Ltd. Process for production of degarelix
ES2385240B1 (es) 2010-07-26 2013-09-23 Gp-Pharm, S.A. Cápsulas de principios activos farmacéuticos y ácidos grasos poliinsaturados para el tratamiento de enfermedades de la próstata.
EP2447276A1 (en) * 2010-10-27 2012-05-02 Ferring B.V. Process for the manufacture of Degarelix and its intermediates
DK2632934T3 (en) * 2010-10-27 2017-01-23 Ferring Bv Process for the preparation of Degarelix and its intermediates
JO3755B1 (ar) * 2011-01-26 2021-01-31 Ferring Bv تركيبات تستوستيرون
CN102204889B (zh) 2011-05-23 2013-09-18 蚌埠丰原涂山制药有限公司 一种醋酸地加瑞克冻干粉针剂及其制备方法
EP2731607B1 (en) * 2011-07-15 2017-10-11 Ferring B.V. Method for timing a colonoscopy wherein a picosulate composition is administered
PL4512389T1 (pl) 2012-06-01 2025-09-01 Ferring B.V. Produkt leczniczy degareliksu

Also Published As

Publication number Publication date
US9579359B2 (en) 2017-02-28
RU2010133481A (ru) 2012-03-20
CY1116341T1 (el) 2017-02-08
SI2249859T1 (sl) 2014-08-29
TWI442932B (zh) 2014-07-01
US20200237854A1 (en) 2020-07-30
ES2540235T3 (es) 2015-07-09
IL223124A0 (en) 2012-12-31
NZ587088A (en) 2012-12-21
EP2650012A1 (en) 2013-10-16
HK1176552A1 (en) 2013-08-02
MX2010008817A (es) 2010-09-09
US20090203622A1 (en) 2009-08-13
JP5924866B2 (ja) 2016-05-25
TW200938217A (en) 2009-09-16
JP2024028869A (ja) 2024-03-05
RU2504394C2 (ru) 2014-01-20
EP2249858A1 (en) 2010-11-17
US20190167755A1 (en) 2019-06-06
JP2016193910A (ja) 2016-11-17
CN101998861A (zh) 2011-03-30
CA3235099A1 (en) 2009-08-20
US20090203623A1 (en) 2009-08-13
EA201300741A1 (ru) 2014-02-28
KR20250028541A (ko) 2025-02-28
EA200901074A1 (ru) 2010-04-30
KR20100126362A (ko) 2010-12-01
SI2650012T1 (sl) 2015-06-30
US10973870B2 (en) 2021-04-13
EP2249859B1 (en) 2014-04-23
AU2009213751B2 (en) 2014-09-25
US9877999B2 (en) 2018-01-30
HRP20140665T1 (hr) 2014-10-10
ZA201005697B (en) 2014-01-24
DK2505204T3 (da) 2015-03-16
HK1145011A1 (en) 2011-03-25
EP4257197A2 (en) 2023-10-11
HK1190912A1 (en) 2014-07-18
WO2009101533A1 (en) 2009-08-20
AU2009213751A1 (en) 2009-08-20
RU2010133480A (ru) 2012-03-20
US11826397B2 (en) 2023-11-28
TW200938218A (en) 2009-09-16
EA017582B1 (ru) 2013-01-30
CY1116289T1 (el) 2017-02-08
CN101939020B (zh) 2012-12-26
KR20100123714A (ko) 2010-11-24
ES2532709T3 (es) 2015-03-31
HK1198243A1 (en) 2015-03-20
KR20140130757A (ko) 2014-11-11
RU2504393C2 (ru) 2014-01-20
JP5876652B2 (ja) 2016-03-02
US20220218783A1 (en) 2022-07-14
IL207295A0 (en) 2010-12-30
US20130029910A1 (en) 2013-01-31
EP2799085A1 (en) 2014-11-05
CA2714445C (en) 2018-01-16
JP2022133426A (ja) 2022-09-13
EA036695B1 (ru) 2020-12-09
EA200901075A1 (ru) 2010-04-30
KR20180118830A (ko) 2018-10-31
JP2011511785A (ja) 2011-04-14
US20220226422A1 (en) 2022-07-21
EA020543B1 (ru) 2014-12-30
CA2714445A1 (en) 2009-08-20
CY1115561T1 (el) 2017-01-04
US10695398B2 (en) 2020-06-30
JP2018039814A (ja) 2018-03-15
JP7400029B2 (ja) 2023-12-18
NZ587057A (en) 2012-12-21
JOP20090061B1 (ar) 2021-08-17
JP2016216455A (ja) 2016-12-22
JP6189234B2 (ja) 2017-08-30
US20140349935A1 (en) 2014-11-27
EP2505204B1 (en) 2014-12-24
IL207400A0 (en) 2010-12-30
NZ603932A (en) 2014-04-30
EP2505204A2 (en) 2012-10-03
KR20150091543A (ko) 2015-08-11
US20220218782A1 (en) 2022-07-14
US20220323538A1 (en) 2022-10-13
US20250134948A1 (en) 2025-05-01
US10729739B2 (en) 2020-08-04
IL207295A (en) 2015-03-31
CN103990107A (zh) 2014-08-20
US20220031801A1 (en) 2022-02-03
HRP20150290T1 (hr) 2015-04-10
US20240316142A1 (en) 2024-09-26
JP2025160167A (ja) 2025-10-22
DK2650012T3 (da) 2015-06-15
IL207400A (en) 2014-12-31
CN107412726A (zh) 2017-12-01
US11766468B2 (en) 2023-09-26
MX2010008816A (es) 2010-09-07
PT2650012E (pt) 2015-06-30
JP2011511786A (ja) 2011-04-14
CA2714444A1 (en) 2009-08-20
JP2014141505A (ja) 2014-08-07
EP4257197A3 (en) 2023-11-29
EP3360565A1 (en) 2018-08-15
US8841081B2 (en) 2014-09-23
JP2014167009A (ja) 2014-09-11
EA026521B1 (ru) 2017-04-28
HRP20150633T1 (hr) 2015-07-31
WO2009101530A1 (en) 2009-08-20
DK2249859T3 (da) 2014-06-02
ES2479441T3 (es) 2014-07-24
US9415085B2 (en) 2016-08-16
PL2650012T3 (pl) 2015-08-31
US20170290879A1 (en) 2017-10-12
EP2650012B1 (en) 2015-03-25
JP2022184898A (ja) 2022-12-13
AU2009213748B2 (en) 2014-03-13
EP2505204A3 (en) 2013-01-09
PL2505204T3 (pl) 2015-05-29
SI2505204T1 (sl) 2015-04-30
BRPI0908129A2 (pt) 2015-08-04
EA201300742A1 (ru) 2014-02-28
KR20230088848A (ko) 2023-06-20
PL2249859T3 (pl) 2014-10-31
US20170035833A1 (en) 2017-02-09
JP6618967B2 (ja) 2019-12-11
AU2009213748A1 (en) 2009-08-20
PT2249859E (pt) 2014-07-31
EP2249859A1 (en) 2010-11-17
US20140113870A1 (en) 2014-04-24
US20210128673A1 (en) 2021-05-06
NZ603958A (en) 2013-03-28
TWI539959B (zh) 2016-07-01
CN101939020A (zh) 2011-01-05
PT2505204E (pt) 2015-03-26
JP6254042B2 (ja) 2017-12-27
KR20220009504A (ko) 2022-01-24
BRPI0908127A2 (pt) 2015-08-04
KR101542480B1 (ko) 2015-08-07

Similar Documents

Publication Publication Date Title
US10973870B2 (en) Methods of treating prostate cancer with GnRH antagonist
US12514898B2 (en) Methods of treating prostate cancer with GnRH antagonist
HK40099992A (en) Treatment of metastatic stage prostate cancer with degarelix
AU2014203174B2 (en) Method of treating prostate cancer with the gnrh antagonist degarelix
HK1258957A1 (en) Treatment of metastatic stage prostate cancer with degarelix
HK1176552B (en) Method of treating prostate cancer with the gnrh antagonist degarelix

Legal Events

Date Code Title Description
SREP Specification republished
FGA Letters patent sealed or granted (standard patent)